Sanara MedTech (SMTI) Stock Price, News & Analysis

Company Overview

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing products for wound care, surgical reconstruction and tissue repair. Its portfolio is designed to support the management of chronic, acute and surgical wounds across a range of clinical settings.

The company’s products include advanced wound matrices, collagen-based products, tissue-repair grafts and antimicrobial solutions. Its offerings include the CellerateRX line of collagen products, BIAKOS antimicrobial wound-care products, Restrata synthetic wound matrices and FORTIFY tissue-repair grafts. These products are intended for use by healthcare professionals in hospitals, outpatient facilities, wound-care centers and other treatment environments.

Sanara MedTech is headquartered in Fort Worth, Texas, and primarily serves the United States through commercial and distribution relationships. The company’s strategy is centered on expanding access to regenerative and advanced wound-care technologies while building a portfolio of products for complex wound-management and surgical applications.

Key Stats

• Today's Range: $34.97 to $35.11
• 50-Day Range: $25.00 to $35.28
• 52-Week Range: $16.05 to $35.34
• Volume: 161,794 shs
• Average Volume: 219,294 shs
• Market Capitalization: $322.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Reduce

Sanara MedTech Stock Analysis - MarketRank™

Sanara MedTech scored higher than 18% of companies evaluated by MarketBeat, and ranked 836th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Reduce

Consensus Rating

Sanara MedTech has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Sanara MedTech is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Sanara MedTech has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanara MedTech is -9.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanara MedTech is -9.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sanara MedTech has a P/B Ratio of 52.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.82% of the float of Sanara MedTech has been sold short.

Short Interest Ratio / Days to Cover

Sanara MedTech has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanara MedTech has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sanara MedTech does not currently pay a dividend.

Dividend Growth

Sanara MedTech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.95

News Sentiment

Sanara MedTech has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Sanara MedTech this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanara MedTech insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.00% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.10% of the stock of Sanara MedTech is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/27/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:SMTI
• CIK: 714256
• Web: www.sanaramedtech.com
• Phone: (817) 529-2300
• Fax: N/A
• Employees: 108
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Sanara MedTech: $35.00
• High Price Target: $35.00
• Low Price Target: $35.00
• Potential Upside/Downside: -0.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 219.13
• P/E Growth: N/A
• Net Income: -$37.56 million
• Net Margins: -29.15%
• Pretax Margin: -0.26%
• Return on Equity: 29.72%
• Return on Assets: 2.84%

Debt

• Debt-to-Equity Ratio: 5.86
• Current Ratio: 2.58
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $109.81 million
• Price / Sales: 2.93
• Cash Flow: $0.59 per share
• Price / Cash Flow: 58.97
• Book Value: $0.67 per share
• Price / Book: 52.33

Miscellaneous

• Outstanding Shares: 9,188,000
• Free Float: 5,329,000
• Market Cap: $322.13 million
• Optionable: Not Optionable
• Beta: 1.16